Multiple Sclerosis: Looking Toward the Future

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

Acute clinical events with stable MRI were more likely among patients with multiple sclerosis who had longer disease duration, received highly effective disease-modifying therapies, and who presented with fatigue.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

A codesigned online nutrition program could potentially fill a need for reliable and evidence-based nutrition information for patients with multiple sclerosis (MS).

Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.